sapunifiram and Neurodegenerative-Diseases

sapunifiram has been researched along with Neurodegenerative-Diseases* in 1 studies

Other Studies

1 other study(ies) available for sapunifiram and Neurodegenerative-Diseases

Article	Year
4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs. Bioorganic & medicinal chemistry letters, 2003, Jul-21, Volume: 13, Issue:14 Extrusion of one of the nitrogens of the piperazine ring of potent nootropic drugs previously described gave 4-aminopiperidine analogues that maintained high cognition enhancing activity in the mouse passive avoidance test. One of the new compounds (9, active at 0.01 mg/kg ip) may represent a new lead for the development of cognition enhancers useful to treat the cognitive deficit produced by neurodegenerative pathologies like Alzheimer's disease. Topics: Amnesia; Animals; Avoidance Learning; Chemical Phenomena; Chemistry, Physical; Cognition; Dose-Response Relationship, Drug; Indicators and Reagents; Mice; Muscarinic Antagonists; Neurodegenerative Diseases; Nootropic Agents; Piperidines; Receptors, AMPA; Scopolamine; Structure-Activity Relationship	2003

Article

Year

4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs.

Bioorganic & medicinal chemistry letters, 2003, Jul-21, Volume: 13, Issue:14

Extrusion of one of the nitrogens of the piperazine ring of potent nootropic drugs previously described gave 4-aminopiperidine analogues that maintained high cognition enhancing activity in the mouse passive avoidance test. One of the new compounds (9, active at 0.01 mg/kg ip) may represent a new lead for the development of cognition enhancers useful to treat the cognitive deficit produced by neurodegenerative pathologies like Alzheimer's disease.

Topics: Amnesia; Animals; Avoidance Learning; Chemical Phenomena; Chemistry, Physical; Cognition; Dose-Response Relationship, Drug; Indicators and Reagents; Mice; Muscarinic Antagonists; Neurodegenerative Diseases; Nootropic Agents; Piperidines; Receptors, AMPA; Scopolamine; Structure-Activity Relationship

2003